Introduction
Hb, 7.5 g/dl; leukocytes, 1.1×109/l (neutrophils, 0.85×109/l ), platelets, 84×109/l; serum creatinine, Felty's syndrome is defined by the triad of rheumatoid 291 mmol/l; total protein, 42 g/l; albumin, 16 g/l; urinarthritis, splenomegaly, and neutropenia, which can ary protein, 17 g/24 h; blood cultures, E. coli. predispose a patient to the development of infections Chlorambucil treatment was stopped and followed that are fundamentally cutaneous, and also infections by a course of antibiotics which met with a good of the respiratory tract.
response. The analysis on leaving the hospital was Hct, In the majority of these patients the bone marrow 24.8%; Hb, 8.7 g/dl; leukocytes, 4.1×109/l (neutroshows an arrest in the maturation of the granulocytes. phils, 2.17×109/l ); platelets, 92×109/l; serum creatinThe pathogenesis is not well known. Several diÂerent ine, 318 mmol/l. mechanisms have been implicated, such as hypersplenOn the 18 February 1995 the patient was admitted ism, maturation defects of myelopoiesis, autoimmune with pneumonia (Haemophilus influenzae) and impaired mechanisms, and a reduction in the production of renal function that required a programme of periodic stimulating factors for the granulocyte colonies.
haemodialysis. Thus, granulocyte macrophage stimulating factor On the 27 July 1995 the patient was admitted (GM-CSF ) [1 ] and granulocyte colony-stimulating suÂering from severe neutropenia ( leukocytes factor (G-CSF ) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] have been successfully used in 1.8×109/l, neutrophils 0.12×109/l ) and splenomegaly, the treatment of neutropenia and infectious complica-being diagnosed as Felty's syndrome. tions associated with Felty's syndrome.
Bone marrow specimen showed an increase in immature forms such as promyelocytes and myelocytes, and a decrease in mature neutrophils, suggesting an arrest Case report in neutrophil maturation.
Treatment with G-CSF was started at a dose of Our patient was a 55-year-old male, in whom seroposi-300 mg/sc/day (5 mg/kg) with early response, showing tive rheumatoid arthritis had been diagnosed in 1988. an increase in both the leukocyte ( 7.8×109/l ) and He had a 30-year history of chronic arthritis, for which neutrophil (4.8×109/l ) counts. G-CSF treatment was he had received treatment with non-steroidal anti-stopped after 5 days. inflammatory agents, gold sodium thiomalate, and An episode of severe neutropenia ( leukocytes D-penicillamine.
2.0×109/l and neutrophils 0.40×109/l ) without further In March 1993, proteinuria was detected following complications occurred on the 16 August 1995. G-CSF the administration of D-penicillamine, which persisted treatment at the same dosage was reinitiated. The after its withdrawal, becoming nephrotic and being appearance after 7 days of leukocytosis ( 16.9×109/l ) accompanied by a slight deterioration in renal function. with neutrophilia (neutrophils 13.4×109/l ) required that the intervals between administration be increased to 3 days a week (subcutaneous, post-dialysis).
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Treatment was halted 44 days later due to leukocytosis On the 18 October 1995, pneumonia coincided with and characteristic of the response. In most cases, however, there is a recovery in the neutrophil count. a new episode of leukopenia 2.4×109/l (neutrophils All cases reported have used subcutaneous administra-0.52×109/l ), for which antibiotics and G-CSF treattion, with the exception of Bhalla et al.
[8] and Fraser ment 300 mg/sc/3 days a week were given. The patient et al.
[15], who administered preliminary doses intraresponded well, although to a lesser extent than that venously. Pixley [16 ] has described a case in which the seen previously. This course of treatment was mainpatient did not respond to the administration of C-GSF tained during 84 days and then reduced to diÂerent alone. Pretreatment with bolus cyclophosphamide perdoses, depending on the neutrophil count, until 239 mitted the growth factor to relieve this impairment of days of continuous treatment had been completed late myeloid maturation and resulted in a brisk, albeit ( Figure 1) .
short, burst of neutrophilia. In others the response The only complication observed during all cycles of improved by the coadministration of methotrexate [18] the treatment with G-CSF was a decrease in the and prednisolone [19 ] . number of platelets, which each time spontaneously
We describe the first case of a patient with Felty's resolved itself after a period of 2 weeks, even during syndrome and CRF caused by secondary amyloidosis the third cycle of treatment ( Figure 1) . undergoing a programme of periodic haemodialysis, Six months after treatment had ceased the patient and who received various cycles of G-CSF treatment remained on a programme of periodic haemodialysis at diÂerent dosages over an extended period of time. without the appearance of any new complications, and
The first two cycles of treatment lasted 5 and 44 with the neutrophil count within a normal range. days respectively and were started after the appearance of severe neutropenia in the analytical controls. The third cycle was started following the reappearance of Discussion neutropenia accompanying pneumonia. During the last cycle, a new episode of asymptomatic neutropenia G-CSF has been used in patients with Felty's syndrome coincided with a reduction in the dosage of G-CSF to for the treatment of neutropenia and infectious com-300 mg/ week s.c. plications [2-14] or in association with prednisone [15 ] The good response and the absence of serious comcyclophosphamide [16,17], methotrexate [18] or plications led us to slowly reduce the doses of G-CSF prednisolone [19 ] .
until the completion of 239 days of treatment. In all There are no general guidelines for treatment with cycles the treatment produced at a very early stage a G-CSF in patients with Felty's syndrome, particularly rapid recovery in the neutrophil count and a resolution of the infectious processes. with respect to the dosage quantities, the duration, 
